Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Arbourmarkon Mar 12, 2021 8:13pm
142 Views
Post# 32791389

RE:RE:RE:RE:RE:Let's Shifting Gears Here. Another Question 4 Anyone or All:

RE:RE:RE:RE:RE:Let's Shifting Gears Here. Another Question 4 Anyone or All:Thank you Bithorse for your in-depth synopsis and connecting the dots. I participated in one of their bought deals and purchased 975,000 shares and received 975,000 warrants.

I had a similar feeling and concerns why they were not completing small trials. I lost faith in management months ago and sold my shares and recovered 95% of my initial investment and still holding the warrants with hopes the Covid-19 phase 2 results prove to be positive but based on your comments and managements track record I have doubts they can complete a phase 3 and might have issues raising the funds necessary to do so.

In my opinion our best hope is we get positive phase 2 data results and they partner with a bigger partner who can take it to the finish line or they buy the rights to the drug for the treatments.

I am not feeling confident.
<< Previous
Bullboard Posts
Next >>